Article Hero

Johnson & Johnson posts better than expected Q2 earnings

Miguel A. Rodriguez
Miguel A. Rodriguez
14 September 2020
Although it was affected by the pandemic, the company had good results.

The 130 years old medical devices, pharmaceutical, and consumer packaged goods developer and innovator,Johnson & Johnson, posted its Q2 financial report. 

Compared to the same time last year, the quarterly profit dropped 35%, since hospitals had to delay elective surgeries due to the pandemic. This situation impacted the medical devices business.

In the past three months, J&J had an EPS of $1.36, which totaled $3.63 billion. Last year it reported an income of $5.6 billion.

The revenue came in at $18.3 billion, higher than the expected $17.6 billion. However, it is 10% lower compared to last year's. The EPS was $1.67, higher than $1.49 expected by specialists.

Unlike other companies which didn't provide any further financial guidance, Johnson & Johnson revealed its forecasts.  For the whole year, it expects an adjusted EPS of up to $7.95 from a previous high of $7.90. The sales were increased from a high of $80.5 billion to $81.4 billion.

Also, the company generated revenue of $10.7 billion in the pharmaceutical business, a 21% increase from last year. The numbers went up due to the COVID-19 vaccine that it is currently working on. According to J&J’s CEO, the human trial will start next week.

The company’s stock price was less than 1% higher during pre-market trading. 







Miguel A. Rodriguez
Miguel A. Rodriguez

Miguel worked for major financial institutions such as Banco Santander, and Banco Central-Hispano. He is a published author of currency trading books.